Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. The company's lead product, AeroVanc (vancomycin hydrochloride inhalation powder), is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/12/12 | $8,600,000 | Series B |
Keiretsu Forum | undisclosed |
